[Pharmacodynamics of a new antiemetic banzamide derivative: amino-4-N-(cyclohexyl-1-pyrrolidinyl-3)N-methylbenzamide fumarate].
D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D000932:Antiemetics; D001058:Apomorphine; D001341:Autonomic Nervous System / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D008297:Male; D051379:Mice; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D014149:Tranquilizing Agents; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D000662:Amphetamines; D000932:Antiemetics; D001549:Benzamides; D011759:Pyrrolidines; D014149:Tranquilizing Agents; D001058:Apomorphine
Profil pharmacodynamique d'un nouvel antiémétique dérivé des benzamides: le fumarate d'amino-4 N-(cyclohexyl-1-pyrrolidinyl-3) N-méthyl benzamide